Sri Nuvvula
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sri Nuvvula has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Adrian C. Chen
Departments of Medicine and Cardiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, USA
1 shared publication - Amgad N. Makaryus
Northwell Health
1 shared publication Avneet Singh
1 shared publication- Benjamin J. Hirsh
Zucker School of Medicine at Hofstra/Northwell, Department of Cardiology, Northwell Health, Manhasset, New York, USA (Drs Weintraub and Hirsh)
1 shared publication Catherine Pham
Cardiovascular Institute Northwell Health, North Shore University Hospital New Hyde Park New York USA
1 shared publicationGidon Salamatbad
Northwell Health
1 shared publication
Latest Publications
- 28 October 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Concomitant Aveir AR and Micra AV2 Hybrid Leadless Implantation During Infected Pacemaker Extraction
Leadless pacing is an important option for patients with device‐related infections. In those requiring dual‐chamber support, reduced atrial battery longevity due to continuous implant‐to‐implant (i2i) communication remains a concern. While recent software updates now allow for the disablement of i2i communication when clinically appropriate, this mode does not provide atrioventricular synchronous pacing. We describe a case of a hybrid leadless system combining an atrial leadless pacemaker (Aveir AR, Abbott) and a second leadless pacemaker capable of atrial mechanical‐sensed ventricular pacing (Micra AV2, Medtronic) in the setting of extraction of an infected transvenous pacemaker, providing atrial pacing with ventricular backup capability while preserving atrial device longevity.
- 28 October 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Concomitant Aveir AR and Micra AV2 Hybrid Leadless Implantation During Infected Pacemaker Extraction
Leadless pacing is an important option for patients with device‐related infections. In those requiring dual‐chamber support, reduced atrial battery longevity due to continuous implant‐to‐implant (i2i) communication remains a concern. While recent software updates now allow for the disablement of i2i communication when clinically appropriate, this mode does not provide atrioventricular synchronous pacing. We describe a case of a hybrid leadless system combining an atrial leadless pacemaker (Aveir AR, Abbott) and a second leadless pacemaker capable of atrial mechanical‐sensed ventricular pacing (Micra AV2, Medtronic) in the setting of extraction of an infected transvenous pacemaker, providing atrial pacing with ventricular backup capability while preserving atrial device longevity.
- Open Access
- 19 September 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (43)
Renal Denervation for Uncontrolled Hypertension in a Patient With Mast Cell Activation Syndrome
- 19 September 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (43)
Open AccessRenal Denervation for Uncontrolled Hypertension in a Patient With Mast Cell Activation Syndrome
- Open Access
- 5 January 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 25, 101411
Quality-of-life and functional outcomes in virtual vs traditional cardiac rehabilitation: A retrospective cohort study
- 5 January 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 25, 101411
Open AccessQuality-of-life and functional outcomes in virtual vs traditional cardiac rehabilitation: A retrospective cohort study
- Open Access
- 29 October 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (10)
Traditional and Virtual Cardiac Rehabilitation: Understanding the Changing Landscape of Cardiac Rehabilitation and the Implications on Patient Outcomes
Cardiac rehabilitation (CR) has been categorized as a class Ia recommendation for secondary prevention after major cardiac interventions or in patients with certain cardiac comorbidities. The benefits of CR have been established and range from reducing readmissions to improving quality of life. Given the increasing amount of literature on CR over the past few years and the evolution of this field, there is a need to synthesize these data. Thus, this review aims to combine the latest research findings to provide a comprehensive review of CR literature. We discuss the components needed to create a successful CR program, including individualized training plans, routine clinical assessments, exercise supervision, and nutritional assessments. Overall rates of CR utilization remain low. Therefore, we explore potential reasons for this underutilization observed in the literature, including CR deserts, under-referral, and the lack of education on benefits, time, and transportation. Moreover, we discuss solutions for underutilization that have been analyzed in the literature, including motivational interviewing, gender-specific regimens, transportation assistance, and automatic referrals. Realizing the underutilization of CR, we also assess virtual CR (VCR) and variations in various regimens within the programs. We compare exercise and body metrics, patient outcomes, feasibility, and patient preferences between VCR and traditional CR published in the literature. VCR does not appear to be inferior to conventional CR in many metrics, although more research is needed to compare the two modalities. We recommend that providers explain the outcomes of the two modalities and allow patients to choose the regimen that works best for them. We discuss how VCR may be better suited to patient populations with specific barriers to care. We also discuss the ongoing current CR trials, many of which are focused on solutions to underutilization. Lastly, we further discuss the remaining gaps in the CR literature and areas where future research could be beneficial, such as establishing large-scale VCR studies and studies focused on expanding CR indications.
- 29 October 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (10)
Open AccessTraditional and Virtual Cardiac Rehabilitation: Understanding the Changing Landscape of Cardiac Rehabilitation and the Implications on Patient Outcomes
Cardiac rehabilitation (CR) has been categorized as a class Ia recommendation for secondary prevention after major cardiac interventions or in patients with certain cardiac comorbidities. The benefits of CR have been established and range from reducing readmissions to improving quality of life. Given the increasing amount of literature on CR over the past few years and the evolution of this field, there is a need to synthesize these data. Thus, this review aims to combine the latest research findings to provide a comprehensive review of CR literature. We discuss the components needed to create a successful CR program, including individualized training plans, routine clinical assessments, exercise supervision, and nutritional assessments. Overall rates of CR utilization remain low. Therefore, we explore potential reasons for this underutilization observed in the literature, including CR deserts, under-referral, and the lack of education on benefits, time, and transportation. Moreover, we discuss solutions for underutilization that have been analyzed in the literature, including motivational interviewing, gender-specific regimens, transportation assistance, and automatic referrals. Realizing the underutilization of CR, we also assess virtual CR (VCR) and variations in various regimens within the programs. We compare exercise and body metrics, patient outcomes, feasibility, and patient preferences between VCR and traditional CR published in the literature. VCR does not appear to be inferior to conventional CR in many metrics, although more research is needed to compare the two modalities. We recommend that providers explain the outcomes of the two modalities and allow patients to choose the regimen that works best for them. We discuss how VCR may be better suited to patient populations with specific barriers to care. We also discuss the ongoing current CR trials, many of which are focused on solutions to underutilization. Lastly, we further discuss the remaining gaps in the CR literature and areas where future research could be beneficial, such as establishing large-scale VCR studies and studies focused on expanding CR indications.
- Open Access
- 30 September 2025
- Published by Wiley
Pulse Field Ablation for Atrial Fibrillation: Insights Based on Published Studies and MAUDE Database
Introduction Pulse Field Ablation (PFA) has proven its efficacy and safety profile through multiple studies for atrial fibrillation. However, there is limited insight into the post-market outcomes given the recency of the approvals. Methods Our objective is to characterize the major device and patient complications of PFA in the United States outside the controlled setting of clinical trials using the Manufacturer and User Facility Device Experience (MAUDE) database and review complications shown in published major clinical studies. We used the Food and Drug Administration (FDA) MAUDE Database to assess device and patient complications from PFA technologies. We also discussed all the trials in which PFA was performed and searched through multiple databases. Results From the MAUDE database, there were 649 events reported involving entrapment of the device. Reported structural cardiac events included 295 pericardial effusion events and 150 cardiac tamponade events. After FDA approval, the number of FARAPULSE events was 88 death events and 1,180 injury events. After FDA approval, the number of PulseSelect events was 9 deaths and 220 injury events. There were 50 published studies that described the outcomes of PFA for atrial fibrillation that met our selection criteria. The most common complications were pericardial tamponade (0.00-5.00%), coronary spasm (0.00-5.00%) and stroke (0.00-4.35%). Conclusion The risk of serious adverse events that we reported necessitates continued refinements of device design and operator technique to improve patient outcomes. Establishing a rigorous registry in the early stage of adoption of PFA technology is strongly warranted to identify complications accurately.
- 30 September 2025
- Published by Wiley
Open AccessPulse Field Ablation for Atrial Fibrillation: Insights Based on Published Studies and MAUDE Database
Introduction Pulse Field Ablation (PFA) has proven its efficacy and safety profile through multiple studies for atrial fibrillation. However, there is limited insight into the post-market outcomes given the recency of the approvals. Methods Our objective is to characterize the major device and patient complications of PFA in the United States outside the controlled setting of clinical trials using the Manufacturer and User Facility Device Experience (MAUDE) database and review complications shown in published major clinical studies. We used the Food and Drug Administration (FDA) MAUDE Database to assess device and patient complications from PFA technologies. We also discussed all the trials in which PFA was performed and searched through multiple databases. Results From the MAUDE database, there were 649 events reported involving entrapment of the device. Reported structural cardiac events included 295 pericardial effusion events and 150 cardiac tamponade events. After FDA approval, the number of FARAPULSE events was 88 death events and 1,180 injury events. After FDA approval, the number of PulseSelect events was 9 deaths and 220 injury events. There were 50 published studies that described the outcomes of PFA for atrial fibrillation that met our selection criteria. The most common complications were pericardial tamponade (0.00-5.00%), coronary spasm (0.00-5.00%) and stroke (0.00-4.35%). Conclusion The risk of serious adverse events that we reported necessitates continued refinements of device design and operator technique to improve patient outcomes. Establishing a rigorous registry in the early stage of adoption of PFA technology is strongly warranted to identify complications accurately.